| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | BRD-K37390332 | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | SB 505124 | GDSC1000 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | -0.0065 | 0.9 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |